Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models. / Zabegalov, Konstantin N.; Kolesnikova, Tatiana O.; Khatsko, Sergey L. et al.
In: European Journal of Pharmacology, Vol. 829, 15.06.2018, p. 129-140.Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models
AU - Zabegalov, Konstantin N.
AU - Kolesnikova, Tatiana O.
AU - Khatsko, Sergey L.
AU - Volgin, Andrey D.
AU - Yakovlev, Oleg A.
AU - Amstislavskaya, Tamara G.
AU - Alekseeva, Polina A.
AU - Meshalkina, Darya A.
AU - Friend, Ashton J.
AU - Bao, Wandong
AU - Demin, Konstantin A.
AU - Gainetdinov, Raul R.
AU - Kalueff, Allan V.
N1 - Publisher Copyright: © 2018 Elsevier B.V.
PY - 2018/6/15
Y1 - 2018/6/15
N2 - Antidepressant drugs are currently one of the most prescribed medications. In addition to treatment resistance and side effects of antidepressants, their clinical use is further complicated by antidepressant discontinuation syndrome (ADS). ADS is a common problem in patients following the interruption, dose reduction, or discontinuation of antidepressant drugs. Clinically, ADS resembles a classical drug withdrawal syndrome, albeit differing from it because antidepressants generally do not induce addiction. The growing clinical importance and prevalence of ADS necessitate novel experimental (animal) models of this disorder. Currently available preclinical models of ADS are mainly rodent-based, and study mostly serotonergic antidepressants and their combinations. Here, we systematically assess clinical ADS symptoms and discuss current trends and challenges in the field of experimental (animal) models of ADS. We also outline basic mechanisms underlying ADS pathobiology, evaluate its genetic, pharmacological and environmental determinants, and emphasize how using animal models may help generate important translational insights into human ADS condition, its prevention and therapy.
AB - Antidepressant drugs are currently one of the most prescribed medications. In addition to treatment resistance and side effects of antidepressants, their clinical use is further complicated by antidepressant discontinuation syndrome (ADS). ADS is a common problem in patients following the interruption, dose reduction, or discontinuation of antidepressant drugs. Clinically, ADS resembles a classical drug withdrawal syndrome, albeit differing from it because antidepressants generally do not induce addiction. The growing clinical importance and prevalence of ADS necessitate novel experimental (animal) models of this disorder. Currently available preclinical models of ADS are mainly rodent-based, and study mostly serotonergic antidepressants and their combinations. Here, we systematically assess clinical ADS symptoms and discuss current trends and challenges in the field of experimental (animal) models of ADS. We also outline basic mechanisms underlying ADS pathobiology, evaluate its genetic, pharmacological and environmental determinants, and emphasize how using animal models may help generate important translational insights into human ADS condition, its prevention and therapy.
KW - Animal models
KW - Antidepressants
KW - Depression
KW - Discontinuation syndrome
KW - Side effects
KW - Antidepressive Agents/adverse effects
KW - Animals
KW - Humans
KW - Substance Withdrawal Syndrome/etiology
KW - Disease Models, Animal
UR - http://www.scopus.com/inward/record.url?scp=85046350588&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2018.04.003
DO - 10.1016/j.ejphar.2018.04.003
M3 - Review article
C2 - 29627310
AN - SCOPUS:85046350588
VL - 829
SP - 129
EP - 140
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
SN - 0014-2999
ER -
ID: 13072671